Results
Ten patients received CyA and 10 placebo. As shown in Table 1 all patients except one were female. The mean age and disease duration were similar in both groups. All the patients completed the study. In Table 2 the subjective changes in the oral and ocular symptoms in the two groups are shown. Most of the patients receiving CyA (eight out of 10) experienced definite improvement of xerostomia, while xerophthalmia and parotid gland enlargement remained the same in the two groups. (Table 3) did not show any significant difference after treatment with either CyA or placebo. The histopathological lesion of the labial minor salivary glands remained unchanged in half of the patients treated with CyA, improved in two, and worsened in one. In two patients we were unable to obtain adequate tissue at the end of the study for re-evaluation. In contrast, in the placebo treated group two biopsies showed the same histopathological lesion as before treatment, in six the lesion deteriorated, and in two patients we were unable to obtain tissue for re-evaluation (Table 4) .
During follow up all the laboratory parameters remained unchanged (data not shown). Six out of 10 patients treated with CyA developed hirsutism, which did not occur in any of the placebo treated group. Other clinical side effects were similar in both groups (Table 5) . We wish to thank Ms E E Papanikolaou for excellent secretarial assistance.
